Natural compounds as potential adjuvants to cancer therapy: Preclinical evidence

Traditional chemotherapy is being considered due to hindrances caused by systemic toxicity. Currently, the administration of multiple chemotherapeutic drugs with different biochemical/molecular targets, known as combination chemotherapy, has attained numerous benefits like efficacy enhancement and a...

Full description

Saved in:
Bibliographic Details
Published inBritish journal of pharmacology Vol. 177; no. 6; pp. 1409 - 1423
Main Authors Lin, Shian‐Ren, Chang, Chia‐Hsiang, Hsu, Che‐Fang, Tsai, May‐Jwan, Cheng, Henrich, Leong, Max K., Sung, Ping‐Jyun, Chen, Jian‐Chyi, Weng, Ching‐Feng
Format Journal Article
LanguageEnglish
Published England Blackwell Publishing Ltd 01.03.2020
John Wiley and Sons Inc
Subjects
Adjuvants
Cancer
Cancer therapies
Chemotherapy
Curcumin
Dietary Supplements
Functional foods & nutraceuticals
Herbs
Humans
Matairesinol
Neoplasms - drug therapy
Plant extracts
Resveratrol
Review
Side effects
Themed Section: Review
Toxicity
Online AccessGet full text

Cover

Abstract Traditional chemotherapy is being considered due to hindrances caused by systemic toxicity. Currently, the administration of multiple chemotherapeutic drugs with different biochemical/molecular targets, known as combination chemotherapy, has attained numerous benefits like efficacy enhancement and amelioration of adverse effects that has been broadly applied to various cancer types. Additionally, seeking natural‐based alternatives with less toxicity has become more important. Experimental evidence suggests that herbal extracts such as Solanum nigrum and Claviceps purpurea and isolated herbal compounds (e.g., curcumin, resveratrol, and matairesinol) combined with antitumoral drugs have the potential to attenuate resistance against cancer therapy and to exert chemoprotective actions. Plant products are not free of risks: Herb adverse effects, including herb–drug interactions, should be carefully considered. Linked Articles This article is part of a themed section on The Pharmacology of Nutraceuticals. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v177.6/issuetoc
AbstractList Traditional chemotherapy is being considered due to hindrances caused by systemic toxicity. Currently, the administration of multiple chemotherapeutic drugs with different biochemical/molecular targets, known as combination chemotherapy, has attained numerous benefits like efficacy enhancement and amelioration of adverse effects that has been broadly applied to various cancer types. Additionally, seeking natural-based alternatives with less toxicity has become more important. Experimental evidence suggests that herbal extracts such as Solanum nigrum and Claviceps purpurea and isolated herbal compounds (e.g., curcumin, resveratrol, and matairesinol) combined with antitumoral drugs have the potential to attenuate resistance against cancer therapy and to exert chemoprotective actions. Plant products are not free of risks: Herb adverse effects, including herb-drug interactions, should be carefully considered. LINKED ARTICLES: This article is part of a themed section on The Pharmacology of Nutraceuticals. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v177.6/issuetoc.
Traditional chemotherapy is being considered due to hindrances caused by systemic toxicity. Currently, the administration of multiple chemotherapeutic drugs with different biochemical/molecular targets, known as combination chemotherapy, has attained numerous benefits like efficacy enhancement and amelioration of adverse effects that has been broadly applied to various cancer types. Additionally, seeking natural‐based alternatives with less toxicity has become more important. Experimental evidence suggests that herbal extracts such as Solanum nigrum and Claviceps purpurea and isolated herbal compounds (e.g., curcumin, resveratrol, and matairesinol) combined with antitumoral drugs have the potential to attenuate resistance against cancer therapy and to exert chemoprotective actions. Plant products are not free of risks: Herb adverse effects, including herb–drug interactions, should be carefully considered.Linked ArticlesThis article is part of a themed section on The Pharmacology of Nutraceuticals. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v177.6/issuetoc
Traditional chemotherapy is being considered due to hindrances caused by systemic toxicity. Currently, the administration of multiple chemotherapeutic drugs with different biochemical/molecular targets, known as combination chemotherapy, has attained numerous benefits like efficacy enhancement and amelioration of adverse effects that has been broadly applied to various cancer types. Additionally, seeking natural‐based alternatives with less toxicity has become more important. Experimental evidence suggests that herbal extracts such as Solanum nigrum and Claviceps purpurea and isolated herbal compounds (e.g., curcumin, resveratrol, and matairesinol) combined with antitumoral drugs have the potential to attenuate resistance against cancer therapy and to exert chemoprotective actions. Plant products are not free of risks: Herb adverse effects, including herb–drug interactions, should be carefully considered. Linked Articles This article is part of a themed section on The Pharmacology of Nutraceuticals. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v177.6/issuetoc
Traditional chemotherapy is being considered due to hindrances caused by systemic toxicity. Currently, the administration of multiple chemotherapeutic drugs with different biochemical/molecular targets, known as combination chemotherapy, has attained numerous benefits like efficacy enhancement and amelioration of adverse effects that has been broadly applied to various cancer types. Additionally, seeking natural-based alternatives with less toxicity has become more important. Experimental evidence suggests that herbal extracts such as Solanum nigrum and Claviceps purpurea and isolated herbal compounds (e.g., curcumin, resveratrol, and matairesinol) combined with antitumoral drugs have the potential to attenuate resistance against cancer therapy and to exert chemoprotective actions. Plant products are not free of risks: Herb adverse effects, including herb-drug interactions, should be carefully considered. LINKED ARTICLES: This article is part of a themed section on The Pharmacology of Nutraceuticals. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v177.6/issuetoc.Traditional chemotherapy is being considered due to hindrances caused by systemic toxicity. Currently, the administration of multiple chemotherapeutic drugs with different biochemical/molecular targets, known as combination chemotherapy, has attained numerous benefits like efficacy enhancement and amelioration of adverse effects that has been broadly applied to various cancer types. Additionally, seeking natural-based alternatives with less toxicity has become more important. Experimental evidence suggests that herbal extracts such as Solanum nigrum and Claviceps purpurea and isolated herbal compounds (e.g., curcumin, resveratrol, and matairesinol) combined with antitumoral drugs have the potential to attenuate resistance against cancer therapy and to exert chemoprotective actions. Plant products are not free of risks: Herb adverse effects, including herb-drug interactions, should be carefully considered. LINKED ARTICLES: This article is part of a themed section on The Pharmacology of Nutraceuticals. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v177.6/issuetoc.
Author Sung, Ping‐Jyun
Tsai, May‐Jwan
Chang, Chia‐Hsiang
Cheng, Henrich
Chen, Jian‐Chyi
Leong, Max K.
Weng, Ching‐Feng
Lin, Shian‐Ren
Hsu, Che‐Fang
AuthorAffiliation 3 Neural Regeneration Laboratory, Neurological Institute Taipei Veterans General Hospital Taipei City Taiwan
2 Center for Prevention and Therapy of Gynaecological Cancers, Department of Research Tzu Chi Hospital Hualien Taiwan
7 Department of Basic Medical Science, Center for Transitional Medicine Xiamen Medical College Xiamen China
5 Graduate Institute of Marine Biotechnology National Dong Hwa University Pingtung Taiwan
6 Department of Biotechnology Southern Taiwan University of Science and Technology Tainan City Taiwan
4 Department of Chemistry National Dong Hwa University Hualien Taiwan
1 Department of Life Science and Institute of Biotechnology National Dong Hwa University Hualien Taiwan
AuthorAffiliation_xml – name: 5 Graduate Institute of Marine Biotechnology National Dong Hwa University Pingtung Taiwan
– name: 7 Department of Basic Medical Science, Center for Transitional Medicine Xiamen Medical College Xiamen China
– name: 4 Department of Chemistry National Dong Hwa University Hualien Taiwan
– name: 3 Neural Regeneration Laboratory, Neurological Institute Taipei Veterans General Hospital Taipei City Taiwan
– name: 2 Center for Prevention and Therapy of Gynaecological Cancers, Department of Research Tzu Chi Hospital Hualien Taiwan
– name: 6 Department of Biotechnology Southern Taiwan University of Science and Technology Tainan City Taiwan
– name: 1 Department of Life Science and Institute of Biotechnology National Dong Hwa University Hualien Taiwan
Author_xml – sequence: 1
  givenname: Shian‐Ren
  orcidid: 0000-0002-4160-2361
  surname: Lin
  fullname: Lin, Shian‐Ren
  organization: National Dong Hwa University
– sequence: 2
  givenname: Chia‐Hsiang
  surname: Chang
  fullname: Chang, Chia‐Hsiang
  organization: National Dong Hwa University
– sequence: 3
  givenname: Che‐Fang
  surname: Hsu
  fullname: Hsu, Che‐Fang
  organization: Tzu Chi Hospital
– sequence: 4
  givenname: May‐Jwan
  surname: Tsai
  fullname: Tsai, May‐Jwan
  organization: Taipei Veterans General Hospital
– sequence: 5
  givenname: Henrich
  surname: Cheng
  fullname: Cheng, Henrich
  organization: Taipei Veterans General Hospital
– sequence: 6
  givenname: Max K.
  surname: Leong
  fullname: Leong, Max K.
  organization: National Dong Hwa University
– sequence: 7
  givenname: Ping‐Jyun
  surname: Sung
  fullname: Sung, Ping‐Jyun
  organization: National Dong Hwa University
– sequence: 8
  givenname: Jian‐Chyi
  surname: Chen
  fullname: Chen, Jian‐Chyi
  organization: Southern Taiwan University of Science and Technology
– sequence: 9
  givenname: Ching‐Feng
  orcidid: 0000-0002-9747-8697
  surname: Weng
  fullname: Weng, Ching‐Feng
  email: cfweng-cfweng@hotmail.com
  organization: Xiamen Medical College
BackLink https://www.ncbi.nlm.nih.gov/pubmed/31368509$$D View this record in MEDLINE/PubMed
BookMark eNp1kcFu1DAQhi1URLeFAy-AInGBQ1o7TmKHAxJUQJEq2AOcrYkzy3qVtYPtLNq3Z8puEVTgi62Zb_75x3PGTnzwyNhTwS8Enct-Wl-IWov2AVuIWrVlI7U4YQvOuSqF0PqUnaW04ZySqnnETqWQrW54t2DLT5DnCGNhw3YKsx9SAamYQkafHYVh2Mw78DkVORQWvMVY5DVGmPavimVEOzrvLIG4cwNS-jF7uIIx4ZPjfc6-vn_35eq6vPn84ePVm5vSUt-2rGUP1vaVRNHbjl4oVxxg1XUoqkEJOVgN5BI6q6USHBXYqlV6aFoKVIM8Z68PutPcb3Gw5JfGMFN0W4h7E8CZvzPerc23sDOKN23daBJ4cRSI4fuMKZutSxbHETyGOZmK2qladXVH6PN76CbM0dN4ppKKq5oLJYl69qej31buPpuAywNgY0gp4spYlyG7cGvQjUZwc7tOQ-s0v9ZJFS_vVdyJ_os9qv9wI-7_D5q3y-tDxU_3Q7AZ
CitedBy_id crossref_primary_10_1016_j_phymed_2022_154046
crossref_primary_10_3892_br_2023_1665
crossref_primary_10_1016_j_sajb_2024_12_012
crossref_primary_10_1038_s41419_024_06902_4
crossref_primary_10_2174_012772574X274566231220051254
crossref_primary_10_3390_app12125818
crossref_primary_10_3390_jcm13154493
crossref_primary_10_1186_s12645_024_00297_9
crossref_primary_10_1002_cbin_11463
crossref_primary_10_3390_biomedicines11061709
crossref_primary_10_1007_s00262_024_03662_0
crossref_primary_10_1002_biof_1915
crossref_primary_10_1080_08923973_2021_1936013
crossref_primary_10_3390_ijms23010431
crossref_primary_10_1007_s10735_024_10247_9
crossref_primary_10_3389_fonc_2022_999667
crossref_primary_10_1007_s12032_024_02339_z
crossref_primary_10_1016_j_jep_2021_114391
crossref_primary_10_1080_01635581_2021_1934043
crossref_primary_10_3389_fphar_2024_1362739
crossref_primary_10_1016_j_ejphar_2020_173709
crossref_primary_10_1007_s11033_025_10300_0
crossref_primary_10_3390_cancers12082147
crossref_primary_10_3390_cancers12113096
crossref_primary_10_3390_biom14080922
crossref_primary_10_3390_cimb46010055
crossref_primary_10_1080_1061186X_2022_2069782
crossref_primary_10_1007_s00210_024_03196_3
crossref_primary_10_1016_j_phrs_2020_105199
crossref_primary_10_1016_j_phrs_2019_104625
crossref_primary_10_3389_fphar_2023_1146741
crossref_primary_10_2174_1566524022666220616141725
crossref_primary_10_3389_fonc_2023_1276654
crossref_primary_10_1007_s10555_023_10148_5
crossref_primary_10_15296_ijwhr_2023_8007
crossref_primary_10_1016_j_indcrop_2021_114360
crossref_primary_10_1016_j_semcancer_2020_05_015
crossref_primary_10_3892_ol_2024_14694
crossref_primary_10_3390_cancers15020399
crossref_primary_10_3390_molecules27154834
crossref_primary_10_1016_j_prostaglandins_2024_106884
crossref_primary_10_1166_jbt_2022_3105
crossref_primary_10_5650_jos_ess23176
crossref_primary_10_1016_j_intimp_2024_112613
crossref_primary_10_1007_s12032_024_02506_2
crossref_primary_10_1186_s13765_021_00599_1
crossref_primary_10_3389_fmolb_2022_752668
crossref_primary_10_1080_07391102_2022_2121323
crossref_primary_10_1016_j_biopha_2021_112531
crossref_primary_10_3390_ijms232416091
crossref_primary_10_2174_0118715206328175241022081832
crossref_primary_10_1371_journal_pone_0312414
crossref_primary_10_1016_j_bcab_2023_102629
crossref_primary_10_3390_cancers13020328
crossref_primary_10_3390_toxics9020024
crossref_primary_10_1002_cbf_3865
crossref_primary_10_3390_ijms242115555
crossref_primary_10_3390_molecules29061404
crossref_primary_10_1016_j_lfs_2020_118100
crossref_primary_10_1155_2021_8849568
crossref_primary_10_3390_ph17050598
crossref_primary_10_3390_app122211545
crossref_primary_10_1007_s12010_024_05094_z
crossref_primary_10_3389_fchem_2024_1352009
crossref_primary_10_3390_nu13124313
crossref_primary_10_1016_j_ejphar_2023_175632
crossref_primary_10_1016_j_colsurfa_2025_136448
crossref_primary_10_3390_pharmaceutics13121993
crossref_primary_10_7759_cureus_49249
crossref_primary_10_3390_molecules26237200
crossref_primary_10_3389_fnut_2022_863619
crossref_primary_10_1016_j_bcp_2025_116749
crossref_primary_10_1016_j_ijbiomac_2023_125364
crossref_primary_10_1016_j_phyplu_2022_100268
crossref_primary_10_3390_ijms222111486
crossref_primary_10_3390_ph15040410
crossref_primary_10_33393_dti_2024_3219
crossref_primary_10_3389_fphar_2024_1491802
crossref_primary_10_3390_toxics11020182
crossref_primary_10_3390_ijms22137178
crossref_primary_10_1155_2022_1850305
crossref_primary_10_1111_bph_70014
crossref_primary_10_1007_s12010_021_03744_0
crossref_primary_10_3390_pharmaceutics15041317
crossref_primary_10_1038_s41420_024_02223_9
crossref_primary_10_3390_molecules29102388
crossref_primary_10_3390_plants12203549
crossref_primary_10_1002_biof_1944
crossref_primary_10_3389_fgene_2022_960263
crossref_primary_10_3390_biom14111382
crossref_primary_10_1111_cpr_13246
crossref_primary_10_3390_ijms231911653
crossref_primary_10_1016_j_cej_2022_139367
crossref_primary_10_3390_molecules25225265
crossref_primary_10_1111_cbdd_13933
crossref_primary_10_3390_ijms21165622
crossref_primary_10_1515_tjb_2023_0210
crossref_primary_10_1007_s00210_025_03899_1
crossref_primary_10_3390_pharmaceutics15061612
crossref_primary_10_1002_ptr_6780
crossref_primary_10_1111_bph_15006
crossref_primary_10_2174_0118715257262003231031171910
crossref_primary_10_1016_j_fitote_2023_105571
crossref_primary_10_1021_acsomega_4c01914
crossref_primary_10_1111_cbdd_14231
crossref_primary_10_2174_1871520621666210706142157
crossref_primary_10_1016_j_phymed_2022_154411
crossref_primary_10_1038_s41389_025_00544_7
crossref_primary_10_1007_s10924_024_03391_6
crossref_primary_10_3390_molecules25225252
crossref_primary_10_3389_fphar_2022_878724
crossref_primary_10_1016_j_molmed_2022_12_002
crossref_primary_10_1016_j_ijbiomac_2024_133861
crossref_primary_10_2478_abm_2024_0010
crossref_primary_10_1016_j_cbi_2022_109832
crossref_primary_10_1089_jmf_2022_K_0112
crossref_primary_10_1002_ptr_7189
crossref_primary_10_3390_biology10030235
crossref_primary_10_2478_ahem_2022_0014
crossref_primary_10_1002_lsm_23469
crossref_primary_10_1002_ptr_7747
crossref_primary_10_1016_j_gendis_2022_02_007
crossref_primary_10_3389_fimmu_2025_1549890
crossref_primary_10_1080_10408398_2022_2036095
crossref_primary_10_2174_1871520620999200730170844
crossref_primary_10_1002_cbf_3944
crossref_primary_10_1007_s11030_024_10999_2
crossref_primary_10_1080_00498254_2021_1929557
crossref_primary_10_1016_j_fbio_2024_104420
crossref_primary_10_3390_antiox10121962
crossref_primary_10_1016_j_sajb_2024_06_028
crossref_primary_10_1039_D2FO01663J
crossref_primary_10_1007_s11033_022_07861_9
crossref_primary_10_1007_s10495_021_01691_z
crossref_primary_10_1016_j_ejphar_2020_173657
crossref_primary_10_1016_j_biopha_2022_113610
crossref_primary_10_3390_life13071422
crossref_primary_10_3389_fonc_2023_1251895
crossref_primary_10_2174_1871520623666230120094158
crossref_primary_10_3390_vaccines10101746
crossref_primary_10_3390_biomedicines11041021
crossref_primary_10_1080_10408398_2021_1913091
crossref_primary_10_3389_fphar_2023_1219362
crossref_primary_10_3390_ijms242216507
crossref_primary_10_1615_CritRevEukaryotGeneExpr_2024055447
crossref_primary_10_1111_and_13786
crossref_primary_10_1002_tox_24308
crossref_primary_10_1080_1062936X_2022_2096113
crossref_primary_10_1111_1541_4337_70118
crossref_primary_10_18632_aging_203019
crossref_primary_10_2174_0118715206308864240823095507
crossref_primary_10_3390_biomedicines10030713
crossref_primary_10_3390_pharmaceutics13010020
crossref_primary_10_53411_jpadr_2022_3_3_05
crossref_primary_10_3390_bioengineering12010007
crossref_primary_10_3390_ijms22168586
crossref_primary_10_3390_cancers14030754
crossref_primary_10_3389_fphar_2021_703761
crossref_primary_10_3390_cancers14215203
crossref_primary_10_3390_app12136531
crossref_primary_10_3390_nu14194166
crossref_primary_10_1016_j_jds_2024_06_016
crossref_primary_10_1016_j_pscia_2023_100029
crossref_primary_10_1080_15287394_2022_2048153
crossref_primary_10_3390_antiox13121533
crossref_primary_10_2174_1871520620666200811121400
crossref_primary_10_1016_j_bpc_2024_107291
crossref_primary_10_1016_j_jddst_2023_104537
crossref_primary_10_1016_j_cbi_2022_110202
crossref_primary_10_3390_molecules27196425
crossref_primary_10_1007_s00432_022_04276_8
crossref_primary_10_3390_biology11081098
crossref_primary_10_4014_jmb_2110_10019
crossref_primary_10_3390_ijms221910619
crossref_primary_10_2174_0109298673343133241011072425
crossref_primary_10_3390_biom14111454
crossref_primary_10_1016_j_bcab_2023_102908
crossref_primary_10_3390_nu16152392
crossref_primary_10_1007_s12032_025_02606_7
crossref_primary_10_1016_j_ijpharm_2021_120870
crossref_primary_10_3390_molecules27113478
crossref_primary_10_3390_antiox10101591
crossref_primary_10_1177_1934578X221105691
crossref_primary_10_1016_j_jics_2021_100293
crossref_primary_10_1155_2022_2923967
crossref_primary_10_1016_j_fbio_2023_103095
crossref_primary_10_3390_ijms24065795
crossref_primary_10_3390_biomedicines11020593
crossref_primary_10_3390_cancers13122940
crossref_primary_10_1016_j_biopha_2022_113128
crossref_primary_10_3390_foods11050668
crossref_primary_10_3390_ph17101356
crossref_primary_10_1042_BSR20210670
crossref_primary_10_2174_1574362417666220329152528
crossref_primary_10_4103_ijnpnd_ijnpnd_18_24
crossref_primary_10_1080_14786419_2022_2121825
crossref_primary_10_3390_targets2020007
crossref_primary_10_2147_IJN_S401038
crossref_primary_10_3390_ijms25116120
crossref_primary_10_1016_j_cellsig_2022_110434
crossref_primary_10_1016_j_procbio_2024_11_002
crossref_primary_10_33483_jfpau_1232868
crossref_primary_10_1016_j_ejphar_2021_174419
crossref_primary_10_1016_j_jpha_2024_101118
crossref_primary_10_1016_j_phymed_2022_154116
crossref_primary_10_1016_j_biopha_2024_116496
crossref_primary_10_1016_j_mcp_2024_101985
crossref_primary_10_1016_j_jddst_2022_103709
crossref_primary_10_1155_2021_3268136
crossref_primary_10_3389_fendo_2022_1007801
crossref_primary_10_3390_life13020261
crossref_primary_10_1177_08980101241277680
crossref_primary_10_3390_molecules27217358
crossref_primary_10_1016_j_pbiomolbio_2021_04_001
crossref_primary_10_1016_j_fbio_2025_106388
crossref_primary_10_3390_ijms241512397
crossref_primary_10_3390_ijms222111639
crossref_primary_10_33393_dti_2024_3177
crossref_primary_10_3390_molecules25122746
crossref_primary_10_1002_cbdv_202301747
crossref_primary_10_1007_s13205_023_03471_9
crossref_primary_10_3390_ijms25042340
crossref_primary_10_1007_s11033_023_09026_8
crossref_primary_10_1016_j_lfs_2024_122943
crossref_primary_10_1093_nar_gkab913
crossref_primary_10_3390_ijms222111772
crossref_primary_10_1007_s11418_024_01849_4
crossref_primary_10_3390_molecules26041109
crossref_primary_10_2174_0118761429249717230920113227
crossref_primary_10_3389_fphar_2022_863082
crossref_primary_10_3390_cancers16193279
crossref_primary_10_3390_molecules27238367
crossref_primary_10_3390_molecules28155813
crossref_primary_10_1016_j_cbi_2023_110605
crossref_primary_10_2174_0113895575258798230927061557
crossref_primary_10_1016_j_ccmp_2022_100036
crossref_primary_10_1080_10408398_2023_2214818
crossref_primary_10_3390_molecules25214890
crossref_primary_10_3390_ijms25158424
crossref_primary_10_3390_molecules26020317
crossref_primary_10_1080_1744666X_2024_2352484
crossref_primary_10_1155_2023_8306514
crossref_primary_10_3390_molecules27113561
crossref_primary_10_2217_rme_2020_0060
crossref_primary_10_3390_jpm14070685
crossref_primary_10_3390_cells10020332
crossref_primary_10_2174_0113892010280336240227062954
crossref_primary_10_1016_j_lfs_2020_118968
crossref_primary_10_3390_molecules25204608
crossref_primary_10_3390_molecules29143399
crossref_primary_10_1016_j_bcp_2021_114475
crossref_primary_10_3390_antiox12112012
crossref_primary_10_1007_s10989_023_10527_0
crossref_primary_10_1002_cbdv_202300878
crossref_primary_10_3390_molecules26144288
Cites_doi 10.1016/j.jiac.2015.10.001
10.18632/oncotarget.6243
10.1093/nar/gkx1121
10.1111/bph.13882
10.3390/ijms17091588
10.3892/mmr.2015.3513
10.1016/j.drup.2012.02.002
10.1124/dmd.116.073213
10.1016/j.biopha.2018.11.095
10.2147/IJN.S115136
10.1111/jog.13203
10.1111/cpr.12143
10.1159/000265166
10.1016/j.lungcan.2010.08.022
10.1097/MD.0000000000002410
10.1016/j.jep.2017.03.051
10.1016/j.ijrobp.2014.11.031
10.1016/B978-0-323-46144-3.00018-0
10.1016/j.jconrel.2017.05.023
10.1016/j.phymed.2018.01.009
10.1016/j.fitote.2018.02.025
10.1166/jbn.2015.2145
10.3389/fphys.2018.00167
10.1155/2017/3432750
10.1111/j.1442-2050.2012.01397.x
10.1111/j.1742-7843.2005.pto_98.x
10.3390/cancers8020022
10.1158/0008-5472.CAN-16-1151
10.1007/s00204-017-2062-2
10.1177/1534735415588826
10.2174/1389200216666151103120338
10.1111/bph.13880
10.18632/oncotarget.19527
10.1007/s40620-017-0392-z
10.1021/acs.molpharmaceut.6b01076
10.1016/j.chembiol.2013.04.007
10.1111/bph.13883
10.3310/hta17060
10.1007/s10157-017-1448-z
10.1111/bph.13878
10.1016/j.intimp.2015.07.016
10.1016/j.imlet.2018.01.009
10.1016/j.biopha.2017.07.035
10.1016/j.biopha.2018.01.101
10.1016/j.drup.2016.05.001
10.4103/0973-1482.158035
10.15171/apb.2017.041
10.1002/biof.1069
10.1038/aps.2012.208
10.3109/01480545.2015.1036281
10.1016/j.ygyno.2014.01.042
10.1016/j.gendis.2016.01.002
10.1016/j.ejphar.2017.10.043
10.1002/cncr.31248
10.4155/tde.13.149
10.1155/2015/618021
10.3390/cancers6031769
10.1016/j.ctim.2015.03.011
10.3390/ijms18112353
10.1177/1534735415572881
10.1016/j.ccell.2015.10.012
10.1016/j.lfs.2005.12.010
10.1177/1534735417722224
10.2217/nnm.12.126
10.2174/157340311799960645
10.1111/bph.13877
10.3390/cells7080107
10.3390/ijms19030904
10.1016/j.canlet.2015.10.010
10.1080/10715762.2017.1381694
10.1016/j.jep.2011.05.017
10.7150/jca.13754
10.1111/nyas.13387
10.1517/17425255.2014.972933
10.3109/0886022X.2014.991998
10.1142/S0192415X1750063X
10.18632/oncotarget.19048
10.1007/s10637-014-0168-4
10.1016/j.pdpdt.2011.11.002
10.1021/acsnano.7b04092
10.4103/ijpvm.IJPVM_40_17
10.3390/ijms18071412
10.1016/j.ctrv.2017.07.006
10.1007/s10637-010-9616-y
10.1016/j.ejso.2017.05.008
10.1016/j.bcp.2012.11.017
10.1016/j.phymed.2014.04.029
10.1158/1541-7786.MCR-11-0578
10.3390/ijms18010096
10.1016/B978-1-4557-4801-3.00019-9
10.1016/j.fct.2015.06.004
10.1158/1535-7163.MCT-12-0448
10.1177/1534735417753542
10.1016/j.fct.2012.03.059
10.1007/s12072-017-9793-2
10.1038/nature15748
10.1634/theoncologist.2010-0322
10.3892/ijo.2015.3084
ContentType Journal Article
Copyright 2019 The Authors. British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society
2019 The Authors. British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.
2019. This article is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: 2019 The Authors. British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society
– notice: 2019 The Authors. British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.
– notice: 2019. This article is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID 24P
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7QP
7TK
K9.
NAPCQ
7X8
5PM
DOI 10.1111/bph.14816
DatabaseName Wiley Online Library Open Access
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Calcium & Calcified Tissue Abstracts
Neurosciences Abstracts
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
Calcium & Calcified Tissue Abstracts
Neurosciences Abstracts
MEDLINE - Academic
DatabaseTitleList MEDLINE
ProQuest Health & Medical Complete (Alumni)

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: 24P
  name: Wiley Online Library Open Access
  url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html
  sourceTypes: Publisher
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
DocumentTitleAlternate Lin et al
EISSN 1476-5381
EndPage 1423
ExternalDocumentID PMC7056458
31368509
10_1111_bph_14816
BPH14816
Genre reviewArticle
Journal Article
Review
GroupedDBID ---
.3N
.55
.GJ
05W
0R~
1OC
23N
24P
2WC
31~
33P
36B
3O-
3SF
3V.
4.4
52U
52V
53G
5GY
6J9
7RV
7X7
8-0
8-1
88E
8AO
8FE
8FH
8FI
8FJ
8R4
8R5
8UM
A00
AAESR
AAEVG
AAHHS
AAHQN
AAIPD
AAMNL
AANLZ
AAONW
AASGY
AAXRX
AAYCA
AAZKR
ABCUV
ABDBF
ABPVW
ABQWH
ABUWG
ABXGK
ACAHQ
ACCFJ
ACCZN
ACFBH
ACGFO
ACGFS
ACGOF
ACMXC
ACPOU
ACPRK
ACUHS
ACXBN
ACXQS
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADXAS
ADZMN
ADZOD
AEEZP
AEGXH
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFFPM
AFGKR
AFKRA
AFPWT
AFRAH
AFWVQ
AFZJQ
AHBTC
AHMBA
AIACR
AIAGR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
AOIJS
ATUGU
AZBYB
AZVAB
B0M
BAFTC
BAWUL
BBNVY
BENPR
BFHJK
BHBCM
BHPHI
BKEYQ
BMXJE
BPHCQ
BRXPI
BVXVI
C45
CAG
CCPQU
COF
CS3
DCZOG
DIK
DRFUL
DRMAN
DRSTM
DU5
E3Z
EAD
EAP
EAS
EBC
EBD
EBS
ECV
EJD
EMB
EMK
EMOBN
ENC
ESX
EX3
F5P
FUBAC
FYUFA
G-S
GODZA
GX1
H.X
HCIFZ
HGLYW
HMCUK
HYE
HZ~
J5H
KBYEO
LATKE
LEEKS
LH4
LITHE
LK8
LOXES
LSO
LUTES
LW6
LYRES
M1P
M7P
MEWTI
MK0
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
MY~
N9A
NAPCQ
NF~
O66
O9-
OIG
OK1
OVD
P2P
P2W
P4E
PQQKQ
PROAC
PSQYO
Q.N
Q2X
QB0
RIG
ROL
RPM
RWI
SJN
SUPJJ
SV3
TEORI
TR2
TUS
UKHRP
UPT
WBKPD
WH7
WHWMO
WIH
WIJ
WIK
WIN
WOHZO
WOW
WVDHM
WXSBR
X7M
XV2
Y6R
YHG
ZGI
ZXP
ZZTAW
~8M
~S-
AAFWJ
AAYXX
AEYWJ
AGHNM
AGYGG
CITATION
PHGZM
PHGZT
AAMMB
AEFGJ
AGXDD
AIDQK
AIDYY
CGR
CUY
CVF
ECM
EIF
NPM
PJZUB
PPXIY
PQGLB
7QP
7TK
K9.
7X8
5PM
ID FETCH-LOGICAL-c5096-43baccb23e1bc9ccbe3f0aaf99e12d713dc8a136a9c83710e7ac2678d56c832d3
IEDL.DBID 24P
ISSN 0007-1188
1476-5381
IngestDate Thu Aug 21 17:30:51 EDT 2025
Fri Jul 11 01:19:50 EDT 2025
Fri Jul 25 19:25:15 EDT 2025
Mon Jul 21 06:05:33 EDT 2025
Thu Apr 24 22:52:25 EDT 2025
Tue Jul 01 03:00:39 EDT 2025
Wed Jan 22 16:34:20 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 6
Language English
License Attribution
2019 The Authors. British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.
This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c5096-43baccb23e1bc9ccbe3f0aaf99e12d713dc8a136a9c83710e7ac2678d56c832d3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
Shian‐Ren Lin and Chia‐Hsiang Chang contribute equally in this study.
ORCID 0000-0002-4160-2361
0000-0002-9747-8697
OpenAccessLink https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fbph.14816
PMID 31368509
PQID 2370740173
PQPubID 42104
PageCount 15
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_7056458
proquest_miscellaneous_2267747949
proquest_journals_2370740173
pubmed_primary_31368509
crossref_citationtrail_10_1111_bph_14816
crossref_primary_10_1111_bph_14816
wiley_primary_10_1111_bph_14816_BPH14816
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate March 2020
PublicationDateYYYYMMDD 2020-03-01
PublicationDate_xml – month: 03
  year: 2020
  text: March 2020
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
– name: Hoboken
PublicationTitle British journal of pharmacology
PublicationTitleAlternate Br J Pharmacol
PublicationYear 2020
Publisher Blackwell Publishing Ltd
John Wiley and Sons Inc
Publisher_xml – name: Blackwell Publishing Ltd
– name: John Wiley and Sons Inc
References 2015; 37
2017; 7
2017; 8
2013; 26
2010; 15
2013; 27
2006; 78
2018; 129
2018; 124
2017; 43
2013; 20
2015; 33
2004; 23
2015a; 23
2017; 45
2018; 40
2012; 15
2013; 8
2016; 39
2014; 133
2012; 11
2012; 10
2017a; 174
2014; 21
2018; 46
2018; 7
2018; 9
2015; 47
2014; 5
2013; 17
2013; 2013
2015; 84
2011; 71
2017; 77
2010; 115
2018; 818
2015; 91
2014; 6
2018; 31
2011; 29
2017; 203
2014; 10
2015; 12
2011; 137
2015; 14
2015; 6
2015; 17
2017; 2017
2017; 1401
2015; 11
2013; 85
2014; 47
2016; 95
2015; 527
2017; 174
2019; 109
2018; 22
2016; 17
2011; 7
2016; 12
2017; 51
2012; 50
2018; 196
2018; 19
2016; 7
2018; 17
2015; 28
2017; 93
2013; 39
2016; 3
2017; 59
2017; 14
2013; 34
2017; 11
2017b; 174
2017; 12
2015; 2015
2015b; 14
2018; 92
2019
2005; 97
2017
2017; 260
2017; 18
2002b
2015
2002a
2018; 99
2016; 27
2016; 8
2016; 22
2016; 370
2012; 9
e_1_2_7_108_1
e_1_2_7_3_1
e_1_2_7_104_1
e_1_2_7_7_1
e_1_2_7_19_1
e_1_2_7_60_1
e_1_2_7_83_1
e_1_2_7_100_1
e_1_2_7_15_1
e_1_2_7_41_1
e_1_2_7_87_1
e_1_2_7_11_1
e_1_2_7_45_1
e_1_2_7_68_1
e_1_2_7_26_1
e_1_2_7_49_1
Parasramka S. (e_1_2_7_71_1) 2017; 7
National Cancer Institute (e_1_2_7_63_1) 2002
Tai C. J. (e_1_2_7_84_1) 2013; 2013
e_1_2_7_90_1
e_1_2_7_94_1
e_1_2_7_52_1
e_1_2_7_98_1
e_1_2_7_23_1
e_1_2_7_33_1
e_1_2_7_75_1
e_1_2_7_56_1
e_1_2_7_37_1
e_1_2_7_79_1
Below J. (e_1_2_7_13_1) 2019
e_1_2_7_4_1
Pai M. P. (e_1_2_7_69_1) 2015
e_1_2_7_105_1
e_1_2_7_8_1
e_1_2_7_101_1
e_1_2_7_16_1
e_1_2_7_40_1
e_1_2_7_82_1
Wang L. (e_1_2_7_95_1) 2019
e_1_2_7_12_1
e_1_2_7_44_1
e_1_2_7_86_1
e_1_2_7_67_1
e_1_2_7_48_1
e_1_2_7_29_1
Florescu M. (e_1_2_7_28_1) 2013; 8
e_1_2_7_51_1
e_1_2_7_70_1
e_1_2_7_93_1
e_1_2_7_24_1
e_1_2_7_32_1
e_1_2_7_55_1
e_1_2_7_74_1
e_1_2_7_97_1
e_1_2_7_20_1
e_1_2_7_36_1
e_1_2_7_59_1
e_1_2_7_78_1
e_1_2_7_5_1
e_1_2_7_106_1
e_1_2_7_9_1
e_1_2_7_102_1
e_1_2_7_17_1
e_1_2_7_81_1
e_1_2_7_43_1
e_1_2_7_66_1
e_1_2_7_85_1
e_1_2_7_47_1
e_1_2_7_89_1
Angelini A. (e_1_2_7_10_1) 2013; 27
e_1_2_7_73_1
e_1_2_7_50_1
e_1_2_7_92_1
e_1_2_7_25_1
e_1_2_7_31_1
e_1_2_7_77_1
e_1_2_7_54_1
e_1_2_7_96_1
e_1_2_7_21_1
e_1_2_7_35_1
e_1_2_7_58_1
e_1_2_7_39_1
e_1_2_7_6_1
e_1_2_7_107_1
e_1_2_7_80_1
e_1_2_7_103_1
e_1_2_7_18_1
e_1_2_7_61_1
e_1_2_7_2_1
e_1_2_7_14_1
e_1_2_7_42_1
e_1_2_7_88_1
e_1_2_7_65_1
e_1_2_7_46_1
e_1_2_7_27_1
National Cancer Institute (e_1_2_7_62_1) 2002
e_1_2_7_91_1
Olas B. (e_1_2_7_64_1) 2004; 23
e_1_2_7_72_1
e_1_2_7_30_1
e_1_2_7_53_1
e_1_2_7_76_1
e_1_2_7_99_1
e_1_2_7_22_1
e_1_2_7_34_1
e_1_2_7_57_1
e_1_2_7_38_1
References_xml – volume: 78
  start-page: 2131
  year: 2006
  end-page: 2145
  article-title: MDR‐ and CYP3A4‐mediated drug‐herbal interactions
  publication-title: Life Sciences
– volume: 12
  start-page: 1261
  year: 2016
  end-page: 1265
  article-title: (Z)‐3,4,3′,5′‐tetramethoxystilbene, a natural product, induces apoptosis and reduces viability of paclitaxel‐and cisplatin‐resistant osteosarcoma cells
  publication-title: Journal of Cancer Research and Therapeutics
– volume: 45
  start-page: 1157
  year: 2017
  end-page: 1167
  article-title: Anti‐inflammatory and immunostimulatory activities of astragalosides
  publication-title: The American Journal of Chinese Medicine
– volume: 14
  start-page: 212
  year: 2015b
  end-page: 220
  article-title: Traditional herbal medicine as adjunctive therapy for nasopharyngeal cancer: A systematic review and meta‐analysis
  publication-title: Integrative Cancer Therapies
– volume: 174
  start-page: S208
  year: 2017
  end-page: S224
  article-title: The concise guide to PHARMACOLOGY 2017/18: Nuclear hormone receptors
  publication-title: British Journal of Pharmacology
– volume: 8
  start-page: 59950
  year: 2017
  end-page: 59964
  article-title: The molecular mechanisms of chemoresistance in cancers
  publication-title: Oncotarget
– volume: 40
  start-page: 125
  year: 2018
  end-page: 139
  article-title: Recent progress in doxorubicin‐induced cardiotoxicity and protective potential of natural products
  publication-title: Phytomedicine
– volume: 260
  start-page: 78
  year: 2017
  end-page: 91
  article-title: Advances in combination therapy of lung cancer: Rationales, delivery technologies and dosage regimens
  publication-title: Journal of Controlled Release
– volume: 31
  start-page: 15
  year: 2018
  end-page: 25
  article-title: Cisplatin nephrotoxicity: A review of the literature
  publication-title: Journal of Nephrology
– volume: 1401
  start-page: 19
  year: 2017
  end-page: 27
  article-title: Natural products to prevent drug resistance in cancer chemotherapy: A review
  publication-title: Annals of the new York Academy of Sciences
– volume: 115
  start-page: 155
  year: 2010
  end-page: 162
  article-title: Doxorubicin cardiomyopathy
  publication-title: Cardiology
– volume: 14
  start-page: 546
  year: 2015
  end-page: 555
  article-title: Cisplatin‐, doxorubicin‐, and docetaxel‐induced cell death promoted by the aqueous extract of solanum nigrum in human ovarian carcinoma cells
  publication-title: Integrative Cancer Therapies
– volume: 37
  start-page: 280
  year: 2015
  end-page: 284
  article-title: Protective effects of thymol against nephrotoxicity induced by cisplatin with using 99mTc‐DMSA in mice
  publication-title: Renal Failure
– volume: 59
  start-page: 123
  year: 2017
  end-page: 131
  article-title: Incidence and risk of cardiotoxicity in cancer patients treated with targeted therapies
  publication-title: Cancer Treatment Reviews
– volume: 18
  start-page: 2353
  year: 2017
  article-title: Hepatotoxicity of herbal supplements mediated by modulation of cytochrome P450
  publication-title: International Journal of Molecular Sciences
– volume: 2017
  year: 2017
  article-title: Oral Chinese herbal medicine as an adjuvant treatment for chemotherapy, or radiotherapy, induced myelosuppression: A systematic review and meta‐analysis of randomized controlled trials
  publication-title: Evidence‐Based Complementary and Alternative Medicine
– volume: 6
  start-page: 1769
  year: 2014
  end-page: 1792
  article-title: Drug resistance in cancer: An overview
  publication-title: Cancers (Basel)
– volume: 33
  start-page: 32
  year: 2015
  end-page: 44
  article-title: Identification of cellular and molecular factors determining the response of cancer cells to six ergot alkaloids
  publication-title: Investigational New Drugs
– volume: 43
  start-page: 358
  year: 2017
  end-page: 364
  article-title: Response to and toxicity of gemcitabine for recurrent ovarian cancer according to number of previous chemotherapy regimens
  publication-title: The Journal of Obstetrics and Gynaecology Research
– volume: 71
  start-page: 3
  year: 2011
  end-page: 10
  article-title: Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC
  publication-title: Lung Cancer
– volume: 818
  start-page: 241
  year: 2018
  end-page: 253
  article-title: Molecular mechanism of doxorubicin‐induced cardiomyopathy—An update
  publication-title: European Journal of Pharmacology
– year: 2019
– volume: 129
  start-page: 383
  year: 2018
  end-page: 400
  article-title: Sensitization of tumor cells to chemotherapy by natural products: A systematic review of preclinical data and molecular mechanisms
  publication-title: Fitoterapia
– volume: 7
  start-page: 353
  year: 2016
  end-page: 363
  article-title: Ellagic acid and resveratrol prevent the development of cisplatin resistance in the epithelial ovarian cancer cell line A2780
  publication-title: Journal of Cancer
– volume: 18
  start-page: 96
  year: 2017
  article-title: Natural antioxidants in foods and medicinal plants: Extraction, assessment and resources
  publication-title: International Journal of Molecular Sciences
– volume: 95
  year: 2016
  article-title: Chinese herbal medicine for improving quality of life among nonsmall cell lung cancer patients: Overview of systematic reviews and network meta‐analysis
  publication-title: Medicine (Baltimore)
– volume: 3
  start-page: 3
  year: 2016
  end-page: 6
  article-title: Transition to resistance: An unexpected role of the EMT in cancer chemoresistance
  publication-title: Genes & Diseases
– volume: 124
  start-page: 2289
  year: 2018
  end-page: 2298
  article-title: Beyond symptomatic relief for chemotherapy‐induced peripheral neuropathy: Targeting the source
  publication-title: Cancer
– start-page: 252
  year: 2015
  end-page: 262.e252
– volume: 8
  start-page: 76
  year: 2017
  article-title: Prevention of chemotherapy‐induced nephrotoxicity in children with cancer
  publication-title: International Journal of Preventive Medicine
– volume: 10
  start-page: 1496
  year: 2012
  end-page: 1508
  article-title: The Hedgehog receptor patched functions in multidrug transport and chemotherapy resistance
  publication-title: Molecular Cancer Research
– volume: 17
  start-page: 1
  year: 2013
  end-page: 278
  article-title: Clinical effectiveness and cost‐effectiveness of first‐line chemotherapy for adult patients with locally advanced or metastatic non‐small cell lung cancer: A systematic review and economic evaluation
  publication-title: Health Technology Assessment
– volume: 19
  start-page: 904
  year: 2018
  article-title: Profiling prostate cancer therapeutic resistance
  publication-title: International Journal of Molecular Sciences
– volume: 97
  start-page: 74
  year: 2005
  end-page: 79
  article-title: Activity of NADPH‐cytochrome P‐450 reductase of the human heart, liver and lungs in the presence of (−)‐epigallocatechin gallate, quercetin and resveratrol: an in vitro study
  publication-title: Basic & Clinical Pharmacology & Toxicology
– volume: 2015
  start-page: 618021
  year: 2015
  article-title: Organotypic culture of breast tumor explants as a multicellular system for the screening of natural compounds with antineoplastic potential
  publication-title: BioMed Research International
– volume: 34
  start-page: 522
  year: 2013
  end-page: 530
  article-title: Astragaloside II triggers T cell activation through regulation of CD45 protein tyrosine phosphatase activity
  publication-title: Acta Pharmacologica Sinica
– volume: 11
  start-page: 2401
  year: 2012
  end-page: 2409
  article-title: Deficient DNA damage signaling leads to chemoresistance to cisplatin in oral cancer
  publication-title: Molecular Cancer Therapeutics
– volume: 23
  start-page: 315
  year: 2004
  end-page: 326
  article-title: Resveratrol reduces oxidative stress induced by platinum compounds in blood platelets
  publication-title: General Physiology and Biophysics
– volume: 22
  start-page: 210
  year: 2018
  end-page: 244
  article-title: Guidelines for treatment of renal injury during cancer chemotherapy 2016
  publication-title: Clinical and Experimental Nephrology
– volume: 99
  start-page: 598
  year: 2018
  end-page: 607
  article-title: Centaurea albonitens extract enhances the therapeutic effects of Vincristine in leukemic cells by inducing apoptosis
  publication-title: Biomedicine & Pharmacotherapy
– volume: 133
  start-page: 117
  year: 2014
  end-page: 123
  article-title: A systematic review comparing cisplatin and carboplatin plus paclitaxel‐based chemotherapy for recurrent or metastatic cervical cancer
  publication-title: Gynecologic Oncology
– volume: 28
  start-page: 634
  year: 2015
  end-page: 642
  article-title: Nordihydroguaiaretic acid ameliorates cisplatin induced nephrotoxicity and potentiates its anti‐tumor activity in DMBA induced breast cancer in female Sprague‐Dawley rats
  publication-title: International Immunopharmacology
– volume: 92
  start-page: 1
  year: 2018
  end-page: 13
  article-title: Hepatotoxicity of monoterpenes and sesquiterpenes
  publication-title: Archives of Toxicology
– volume: 174
  start-page: S17
  year: 2017
  end-page: S129
  article-title: The concise guide to PHARMACOLOGY 2017/18: G protein‐coupled receptors
  publication-title: British Journal of Pharmacology
– start-page: 455
  year: 2017
  end-page: 484
– volume: 77
  start-page: 198
  year: 2017
  end-page: 206
  article-title: DNA repair capacity in multiple pathways predicts chemoresistance in glioblastoma multiforme
  publication-title: Cancer Research
– volume: 93
  start-page: 1238
  year: 2017
  end-page: 1245
  article-title: Regulatory players of DNA damage repair mechanisms: Role in cancer chemoresistance
  publication-title: Biomedicine & Pharmacotherapy
– volume: 47
  start-page: 840
  year: 2015
  end-page: 848
  article-title: Epithelial‐mesenchymal transition and drug resistance in breast cancer (Review)
  publication-title: International Journal of Oncology
– volume: 45
  start-page: 49
  year: 2017
  end-page: 55
  article-title: Curcumin, Piperine, and capsaicin: A comparative study of spice‐mediated inhibition of human cytochrome P450 isozyme activities
  publication-title: Drug Metabolism and Disposition
– volume: 39
  start-page: 279
  year: 2013
  end-page: 293
  article-title: An ex vivo study of selenium, genistein on the morphological and nuclear changes in anticancer drug‐induced apoptosis in human peripheral blood lymphocytes
  publication-title: BioFactors
– volume: 17
  start-page: 411
  year: 2018
  end-page: 422
  article-title: Complementary Chinese herbal medicine therapy improves survival of patients with pancreatic cancer in Taiwan: A nationwide population‐based cohort study
  publication-title: Integrative Cancer Therapies
– volume: 15
  start-page: 50
  year: 2012
  end-page: 61
  article-title: Targeting MDR in breast and lung cancer: Discriminating its potential importance from the failure of drug resistance reversal studies
  publication-title: Drug Resistance Updates
– volume: 11
  start-page: 8560
  year: 2017
  end-page: 8578
  article-title: Drug delivery strategies for platinum‐based chemotherapy
  publication-title: ACS Nano
– volume: 8
  start-page: 60684
  year: 2017
  end-page: 60703
  article-title: The Hedgehog‐GLI pathway in embryonic development and cancer: Implications for pulmonary oncology therapy
  publication-title: Oncotarget
– volume: 9
  start-page: 167
  year: 2018
  article-title: Antineoplastic drug‐induced cardiotoxicity: A redox perspective
  publication-title: Frontiers in Physiology
– volume: 51
  start-page: 812
  year: 2017
  end-page: 827
  article-title: Attenuation of doxorubicin‐induced cardiotoxicity and genotoxicity by an indole‐based natural compound 3,3′‐diindolylmethane (DIM) through activation of Nrf2/ARE signaling pathways and inhibiting apoptosis
  publication-title: Free Radical Research
– volume: 27
  start-page: 14
  year: 2016
  end-page: 29
  article-title: Overcoming ABC transporter‐mediated multidrug resistance: Molecular mechanisms and novel therapeutic drug strategies
  publication-title: Drug Resistance Updates
– volume: 8
  start-page: 22
  year: 2016
  article-title: Targeting the sonic hedgehog signaling pathway: Review of smoothened and GLI inhibitors
  publication-title: Cancers (Basel)
– volume: 137
  start-page: 231
  year: 2011
  end-page: 235
  article-title: A comparison of the immunostimulatory effects of the medicinal herbs Echinacea, Ashwagandha and Brahmi
  publication-title: Journal of Ethnopharmacology
– volume: 29
  start-page: 666
  year: 2011
  end-page: 673
  article-title: Anoikis induction and metastasis suppression by a new integrin αvβ3 inhibitor in human melanoma cell line M21
  publication-title: Investigational New Drugs
– volume: 8
  start-page: 389
  year: 2013
  end-page: 401
  article-title: Tea phenols in bulk and nanoparticle form modify DNA damage in human lymphocytes from colon cancer patients and healthy individuals treated in vitro with platinum‐based chemotherapeutic drugs
  publication-title: Nanomedicine (London, England)
– volume: 109
  start-page: 2252
  year: 2019
  end-page: 2261
  article-title: Traditional Chinese medicine Gegen Qinlian decoction ameliorates irinotecan chemotherapy‐induced gut toxicity in mice
  publication-title: Biomedicine & Pharmacotherapy
– volume: 203
  start-page: 110
  year: 2017
  end-page: 119
  article-title: Reversal of multidrug resistance by Marsdenia tenacissima and its main active ingredients polyoxypregnanes
  publication-title: Journal of Ethnopharmacology
– year: 2002a
– volume: 15
  start-page: 1102
  year: 2010
  end-page: 1112
  article-title: Future scenarios for the treatment of advanced non‐small cell lung cancer: Focus on taxane‐containing regimens
  publication-title: The Oncologist
– volume: 9
  start-page: 100
  year: 2012
  end-page: 108
  article-title: Combination of Fospeg‐IPDT and a natural antioxidant compound prevents photosensitivity in a murine prostate cancer tumour model
  publication-title: Photodiagnosis and Photodynamic Therapy
– volume: 10
  start-page: 1677
  year: 2014
  end-page: 1690
  article-title: Natural compounds to overcome cancer chemoresistance: Toxicological and clinical issues
  publication-title: Expert Opinion on Drug Metabolism & Toxicology
– volume: 527
  start-page: 472
  year: 2015
  end-page: 476
  article-title: Epithelial‐to‐mesenchymal transition is not required for lung metastasis but contributes to chemoresistance
  publication-title: Nature
– volume: 6
  start-page: 42150
  year: 2015
  end-page: 42168
  article-title: Co‐delivery of cisplatin and paclitaxel by folic acid conjugated amphiphilic PEG‐PLGA copolymer nanoparticles for the treatment of non‐small lung cancer
  publication-title: Oncotarget
– volume: 174
  start-page: S1
  issue: Suppl 1
  year: 2017a
  end-page: S16
  article-title: The concise guide to PHARMACOLOGY 2017/18: Other proteins
  publication-title: British Journal of Pharmacology
– volume: 8
  start-page: 59
  year: 2013
  end-page: 67
  article-title: Chemotherapy‐induced cardiotoxicity
  publication-title: Maedica (Buchar)
– volume: 26
  start-page: 859
  year: 2013
  end-page: 863
  article-title: Agrocybe aegerita polysaccharide combined with chemotherapy improves tumor necrosis factor‐α and interferon‐γ levels in rat esophageal carcinoma
  publication-title: Diseases of the Esophagus
– volume: 370
  start-page: 153
  year: 2016
  end-page: 164
  article-title: Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade
  publication-title: Cancer Letters
– volume: 11
  start-page: 221
  year: 2017
  end-page: 241
  article-title: CSH guidelines for the diagnosis and treatment of drug‐induced liver injury
  publication-title: Hepatology International
– volume: 20
  start-page: 648
  year: 2013
  end-page: 659
  article-title: DNA‐damaging agents in cancer chemotherapy: Serendipity and chemical biology
  publication-title: Chemistry & Biology
– volume: 27
  start-page: 1029
  year: 2013
  end-page: 1037
  article-title: Modulation of multidrug resistance P‐glycoprotein activity by antiemetic compounds in human doxorubicin‐resistant sarcoma cells (MES‐SA/Dx‐5): Implications on cancer therapy
  publication-title: Journal of Biological Regulators and Homeostatic Agents
– volume: 17
  start-page: 1588
  year: 2016
  article-title: Anthocyanin attenuates doxorubicin‐induced cardiomyotoxicity via estrogen receptor‐α/β and stabilizes HSF1 to inhibit the IGF‐IIR apoptotic pathway
  publication-title: International Journal of Molecular Sciences
– volume: 174
  start-page: S272
  year: 2017
  end-page: S359
  article-title: The concise guide to PHARMACOLOGY 2017/18: Enzymes
  publication-title: British Journal of Pharmacology
– volume: 47
  start-page: 506
  year: 2014
  end-page: 515
  article-title: Plant natural products: From traditional compounds to new emerging drugs in cancer therapy
  publication-title: Cell Proliferation
– volume: 2013
  year: 2013
  article-title: Aqueous extract of Solanum nigrum leaves induces autophagy and enhances cytotoxicity of cisplatin, doxorubicin, docetaxel, and 5‐fluorouracil in human colorectal carcinoma cells
  publication-title: Evidence‐Based Complementary and Alternative Medicine
– volume: 12
  start-page: 955
  year: 2017
  end-page: 968
  article-title: Co‐delivery of paclitaxel and TOS‐cisplatin via TAT‐targeted solid lipid nanoparticles with synergistic antitumor activity against cervical cancer
  publication-title: International Journal of Nanomedicine
– volume: 39
  start-page: 87
  year: 2016
  end-page: 96
  article-title: Saffron extracts alleviate cardiomyocytes injury induced by doxorubicin and ischemia‐reperfusion in vitro
  publication-title: Drug and Chemical Toxicology
– volume: 50
  start-page: 1927
  year: 2012
  end-page: 1932
  article-title: Eriodictyol‐7‐O‐glucoside, a novel Nrf2 activator, confers protection against cisplatin‐induced toxicity
  publication-title: Food and Chemical Toxicology
– volume: 21
  start-page: 1110
  year: 2014
  end-page: 1119
  article-title: Tetrandrine and fangchinoline, bisbenzylisoquinoline alkaloids from Stephania tetrandra can reverse multidrug resistance by inhibiting P‐glycoprotein activity in multidrug resistant human cancer cells
  publication-title: Phytomedicine
– volume: 12
  start-page: 1368
  year: 2015
  end-page: 1374
  article-title: Modulatory role of resveratrol on cytotoxic activity of cisplatin, sensitization and modification of cisplatin resistance in colorectal cancer cells
  publication-title: Molecular Medicine Reports
– volume: 14
  start-page: 875
  year: 2017
  end-page: 884
  article-title: Combination therapy of NSCLC using Hsp90 inhibitor and doxorubicin carrying functional nanoceria
  publication-title: Molecular Pharmaceutics
– volume: 174
  start-page: S360
  year: 2017b
  end-page: S446
  article-title: The concise guide to PHARMACOLOGY 2017/18: Transporters
  publication-title: British Journal of Pharmacology
– volume: 91
  start-page: 807
  year: 2015
  end-page: 816
  article-title: Coniferyl aldehyde reduces radiation damage through increased protein stability of heat shock transcriptional factor 1 by phosphorylation
  publication-title: International Journal of Radiation Oncology, Biology, Physics
– volume: 7
  year: 2017
  article-title: Procarbazine, lomustine and vincristine for recurrent high‐grade glioma
  publication-title: Cochrane Database of Systematic Reviews
– volume: 85
  start-page: 486
  year: 2013
  end-page: 496
  article-title: β‐phenylethyl isothiocyanate reverses platinum resistance by a GSH‐dependent mechanism in cancer cells with epithelial‐mesenchymal transition phenotype
  publication-title: Biochemical Pharmacology
– volume: 23
  start-page: 626
  year: 2015a
  end-page: 632
  article-title: Traditional herbal medicine as adjunctive therapy for breast cancer: A systematic review
  publication-title: Complementary Therapies in Medicine
– volume: 22
  start-page: 36
  year: 2016
  end-page: 43
  article-title: Anti‐cancer and cardioprotective effects of indol‐3‐carbinol in doxorubicin‐treated mice
  publication-title: Journal of Infection and Chemotherapy
– volume: 18
  year: 2017
  article-title: Natural compounds from herbs that can potentially execute as autophagy inducers for cancer therapy
  publication-title: International Journal of Molecular Sciences
– volume: 46
  start-page: D1091
  year: 2018
  end-page: D1106
  article-title: The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: Updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY
  publication-title: Nucleic Acids Research
– volume: 196
  start-page: 22
  year: 2018
  end-page: 32
  article-title: CD45 in human physiology and clinical medicine
  publication-title: Immunology Letters
– volume: 28
  start-page: 690
  year: 2015
  end-page: 714
  article-title: Immunological effects of conventional chemotherapy and targeted anticancer agents
  publication-title: Cancer Cell
– volume: 11
  start-page: 1859
  year: 2015
  end-page: 1898
  article-title: Recent developments in active tumor targeted multifunctional nanoparticles for combination chemotherapy in cancer treatment and imaging
  publication-title: Journal of Biomedical Nanotechnology
– volume: 7
  start-page: 214
  year: 2011
  end-page: 220
  article-title: Anthracycline cardiotoxicity: Prevalence, pathogenesis and treatment
  publication-title: Current Cardiology Reviews
– volume: 43
  start-page: 1668
  year: 2017
  end-page: 1681
  article-title: Hepatotoxicity following systemic therapy for colorectal liver metastases and the impact of chemotherapy‐associated liver injury on outcomes after curative liver resection
  publication-title: European Journal of Surgical Oncology
– volume: 5
  start-page: 149
  year: 2014
  end-page: 171
  article-title: Nanoscale particulate systems for multidrug delivery: Towards improved combination chemotherapy
  publication-title: Therapeutic Delivery
– volume: 7
  start-page: 339
  year: 2017
  end-page: 348
  article-title: The different mechanisms of cancer drug resistance: A brief review
  publication-title: Adv Pharm Bull
– volume: 7
  year: 2018
  article-title: Targeting the multidrug transporter ptch1 potentiates chemotherapy efficiency
  publication-title: Cell
– volume: 17
  start-page: 619
  year: 2018
  end-page: 627
  article-title: Benefit of adjuvant traditional herbal medicine with chemotherapy for resectable gastric cancer
  publication-title: Integrative Cancer Therapies
– volume: 17
  start-page: 37
  year: 2015
  end-page: 51
  article-title: Ceramide: Therapeutic potential in combination therapy for cancer treatment
  publication-title: Current Drug Metabolism
– year: 2002b
– year: 2019
  article-title: Wnt1‐inducible signaling protein 1 regulates laryngeal squamous cell carcinoma glycolysis and chemoresistance via the YAP1/TEAD1/GLUT1 pathway
  publication-title: Journal of Cellular Physiology
– volume: 84
  start-page: 47
  year: 2015
  end-page: 54
  article-title: Systematic review on herb‐induced liver injury in Korea
  publication-title: Food and Chemical Toxicology
– ident: e_1_2_7_2_1
  doi: 10.1016/j.jiac.2015.10.001
– ident: e_1_2_7_35_1
  doi: 10.18632/oncotarget.6243
– ident: e_1_2_7_33_1
  doi: 10.1093/nar/gkx1121
– ident: e_1_2_7_6_1
  doi: 10.1111/bph.13882
– year: 2019
  ident: e_1_2_7_95_1
  article-title: Wnt1‐inducible signaling protein 1 regulates laryngeal squamous cell carcinoma glycolysis and chemoresistance via the YAP1/TEAD1/GLUT1 pathway
  publication-title: Journal of Cellular Physiology
– ident: e_1_2_7_42_1
  doi: 10.3390/ijms17091588
– ident: e_1_2_7_67_1
  doi: 10.3892/mmr.2015.3513
– ident: e_1_2_7_9_1
  doi: 10.1016/j.drup.2012.02.002
– ident: e_1_2_7_79_1
  doi: 10.1124/dmd.116.073213
– ident: e_1_2_7_99_1
  doi: 10.1016/j.biopha.2018.11.095
– ident: e_1_2_7_54_1
  doi: 10.2147/IJN.S115136
– ident: e_1_2_7_85_1
  doi: 10.1111/jog.13203
– ident: e_1_2_7_68_1
  doi: 10.1111/cpr.12143
– ident: e_1_2_7_21_1
  doi: 10.1159/000265166
– ident: e_1_2_7_20_1
  doi: 10.1016/j.lungcan.2010.08.022
– ident: e_1_2_7_98_1
  doi: 10.1097/MD.0000000000002410
– ident: e_1_2_7_86_1
  doi: 10.1016/j.jep.2017.03.051
– ident: e_1_2_7_44_1
  doi: 10.1016/j.ijrobp.2014.11.031
– ident: e_1_2_7_66_1
  doi: 10.1016/B978-0-323-46144-3.00018-0
– ident: e_1_2_7_96_1
  doi: 10.1016/j.jconrel.2017.05.023
– ident: e_1_2_7_103_1
  doi: 10.1016/j.phymed.2018.01.009
– ident: e_1_2_7_65_1
  doi: 10.1016/j.fitote.2018.02.025
– volume: 27
  start-page: 1029
  year: 2013
  ident: e_1_2_7_10_1
  article-title: Modulation of multidrug resistance P‐glycoprotein activity by antiemetic compounds in human doxorubicin‐resistant sarcoma cells (MES‐SA/Dx‐5): Implications on cancer therapy
  publication-title: Journal of Biological Regulators and Homeostatic Agents
– ident: e_1_2_7_30_1
  doi: 10.1166/jbn.2015.2145
– ident: e_1_2_7_88_1
  doi: 10.3389/fphys.2018.00167
– ident: e_1_2_7_38_1
  doi: 10.1155/2017/3432750
– ident: e_1_2_7_43_1
  doi: 10.1111/j.1442-2050.2012.01397.x
– ident: e_1_2_7_24_1
  doi: 10.1111/j.1742-7843.2005.pto_98.x
– ident: e_1_2_7_76_1
  doi: 10.3390/cancers8020022
– ident: e_1_2_7_61_1
  doi: 10.1158/0008-5472.CAN-16-1151
– ident: e_1_2_7_106_1
  doi: 10.1007/s00204-017-2062-2
– volume: 2013
  start-page: 514719
  year: 2013
  ident: e_1_2_7_84_1
  article-title: Aqueous extract of Solanum nigrum leaves induces autophagy and enhances cytotoxicity of cisplatin, doxorubicin, docetaxel, and 5‐fluorouracil in human colorectal carcinoma cells
  publication-title: Evidence‐Based Complementary and Alternative Medicine
– volume: 23
  start-page: 315
  year: 2004
  ident: e_1_2_7_64_1
  article-title: Resveratrol reduces oxidative stress induced by platinum compounds in blood platelets
  publication-title: General Physiology and Biophysics
– ident: e_1_2_7_92_1
  doi: 10.1177/1534735415588826
– ident: e_1_2_7_50_1
  doi: 10.2174/1389200216666151103120338
– ident: e_1_2_7_4_1
  doi: 10.1111/bph.13880
– ident: e_1_2_7_11_1
  doi: 10.18632/oncotarget.19527
– ident: e_1_2_7_57_1
  doi: 10.1007/s40620-017-0392-z
– ident: e_1_2_7_82_1
  doi: 10.1021/acs.molpharmaceut.6b01076
– ident: e_1_2_7_23_1
  doi: 10.1016/j.chembiol.2013.04.007
– ident: e_1_2_7_7_1
  doi: 10.1111/bph.13883
– ident: e_1_2_7_16_1
  doi: 10.3310/hta17060
– ident: e_1_2_7_36_1
  doi: 10.1007/s10157-017-1448-z
– ident: e_1_2_7_3_1
  doi: 10.1111/bph.13878
– ident: e_1_2_7_60_1
  doi: 10.1016/j.intimp.2015.07.016
– ident: e_1_2_7_75_1
  doi: 10.1016/j.imlet.2018.01.009
– ident: e_1_2_7_77_1
  doi: 10.1016/j.biopha.2017.07.035
– ident: e_1_2_7_12_1
  doi: 10.1016/j.biopha.2018.01.101
– ident: e_1_2_7_51_1
  doi: 10.1016/j.drup.2016.05.001
– ident: e_1_2_7_101_1
  doi: 10.4103/0973-1482.158035
– ident: e_1_2_7_58_1
  doi: 10.15171/apb.2017.041
– ident: e_1_2_7_81_1
  doi: 10.1002/biof.1069
– ident: e_1_2_7_91_1
  doi: 10.1038/aps.2012.208
– ident: e_1_2_7_19_1
  doi: 10.3109/01480545.2015.1036281
– ident: e_1_2_7_55_1
  doi: 10.1016/j.ygyno.2014.01.042
– ident: e_1_2_7_93_1
  doi: 10.1016/j.gendis.2016.01.002
– ident: e_1_2_7_74_1
  doi: 10.1016/j.ejphar.2017.10.043
– ident: e_1_2_7_56_1
  doi: 10.1002/cncr.31248
– ident: e_1_2_7_52_1
  doi: 10.4155/tde.13.149
– ident: e_1_2_7_18_1
  doi: 10.1155/2015/618021
– ident: e_1_2_7_39_1
  doi: 10.3390/cancers6031769
– ident: e_1_2_7_46_1
  doi: 10.1016/j.ctim.2015.03.011
– volume-title: Breast cancer treatment (PDQ(R)): Health professional version
  year: 2002
  ident: e_1_2_7_62_1
– ident: e_1_2_7_15_1
  doi: 10.3390/ijms18112353
– ident: e_1_2_7_45_1
  doi: 10.1177/1534735415572881
– volume: 7
  start-page: CD011773
  year: 2017
  ident: e_1_2_7_71_1
  article-title: Procarbazine, lomustine and vincristine for recurrent high‐grade glioma
  publication-title: Cochrane Database of Systematic Reviews
– ident: e_1_2_7_29_1
  doi: 10.1016/j.ccell.2015.10.012
– ident: e_1_2_7_70_1
  doi: 10.1016/j.lfs.2005.12.010
– ident: e_1_2_7_47_1
  doi: 10.1177/1534735417722224
– ident: e_1_2_7_8_1
  doi: 10.2217/nnm.12.126
– ident: e_1_2_7_89_1
  doi: 10.2174/157340311799960645
– ident: e_1_2_7_5_1
  doi: 10.1111/bph.13877
– ident: e_1_2_7_34_1
  doi: 10.3390/cells7080107
– ident: e_1_2_7_90_1
  doi: 10.3390/ijms19030904
– ident: e_1_2_7_22_1
  doi: 10.1016/j.canlet.2015.10.010
– ident: e_1_2_7_32_1
  doi: 10.1080/10715762.2017.1381694
– ident: e_1_2_7_102_1
  doi: 10.1016/j.jep.2011.05.017
– ident: e_1_2_7_26_1
  doi: 10.7150/jca.13754
– ident: e_1_2_7_105_1
  doi: 10.1111/nyas.13387
– ident: e_1_2_7_87_1
  doi: 10.1517/17425255.2014.972933
– ident: e_1_2_7_37_1
  doi: 10.3109/0886022X.2014.991998
– ident: e_1_2_7_73_1
  doi: 10.1142/S0192415X1750063X
– ident: e_1_2_7_108_1
  doi: 10.18632/oncotarget.19048
– ident: e_1_2_7_59_1
  doi: 10.1007/s10637-014-0168-4
– ident: e_1_2_7_72_1
  doi: 10.1016/j.pdpdt.2011.11.002
– ident: e_1_2_7_17_1
  doi: 10.1021/acsnano.7b04092
– ident: e_1_2_7_80_1
  doi: 10.4103/ijpvm.IJPVM_40_17
– ident: e_1_2_7_53_1
  doi: 10.3390/ijms18071412
– ident: e_1_2_7_78_1
  doi: 10.1016/j.ctrv.2017.07.006
– ident: e_1_2_7_107_1
  doi: 10.1007/s10637-010-9616-y
– ident: e_1_2_7_25_1
  doi: 10.1016/j.ejso.2017.05.008
– ident: e_1_2_7_97_1
  doi: 10.1016/j.bcp.2012.11.017
– ident: e_1_2_7_83_1
  doi: 10.1016/j.phymed.2014.04.029
– ident: e_1_2_7_14_1
  doi: 10.1158/1541-7786.MCR-11-0578
– volume-title: Non‐small cell lung cancer treatment (PDQ(R)): Health professional version
  year: 2002
  ident: e_1_2_7_63_1
– ident: e_1_2_7_100_1
  doi: 10.3390/ijms18010096
– volume-title: Vincristine
  year: 2019
  ident: e_1_2_7_13_1
– start-page: 252
  volume-title: Mandell, Douglas, and Bennett's principles and practice of infectious diseases
  year: 2015
  ident: e_1_2_7_69_1
  doi: 10.1016/B978-1-4557-4801-3.00019-9
– volume: 8
  start-page: 59
  year: 2013
  ident: e_1_2_7_28_1
  article-title: Chemotherapy‐induced cardiotoxicity
  publication-title: Maedica (Buchar)
– ident: e_1_2_7_48_1
  doi: 10.1016/j.fct.2015.06.004
– ident: e_1_2_7_94_1
  doi: 10.1158/1535-7163.MCT-12-0448
– ident: e_1_2_7_49_1
  doi: 10.1177/1534735417753542
– ident: e_1_2_7_40_1
  doi: 10.1016/j.fct.2012.03.059
– ident: e_1_2_7_104_1
  doi: 10.1007/s12072-017-9793-2
– ident: e_1_2_7_27_1
  doi: 10.1038/nature15748
– ident: e_1_2_7_31_1
  doi: 10.1634/theoncologist.2010-0322
– ident: e_1_2_7_41_1
  doi: 10.3892/ijo.2015.3084
SSID ssj0014775
Score 2.677209
SecondaryResourceType review_article
Snippet Traditional chemotherapy is being considered due to hindrances caused by systemic toxicity. Currently, the administration of multiple chemotherapeutic drugs...
SourceID pubmedcentral
proquest
pubmed
crossref
wiley
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 1409
SubjectTerms Adjuvants
Cancer
Cancer therapies
Chemotherapy
Curcumin
Dietary Supplements
Functional foods & nutraceuticals
Herbs
Humans
Matairesinol
Neoplasms - drug therapy
Plant extracts
Resveratrol
Review
Side effects
Themed Section: Review
Toxicity
Title Natural compounds as potential adjuvants to cancer therapy: Preclinical evidence
URI https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fbph.14816
https://www.ncbi.nlm.nih.gov/pubmed/31368509
https://www.proquest.com/docview/2370740173
https://www.proquest.com/docview/2267747949
https://pubmed.ncbi.nlm.nih.gov/PMC7056458
Volume 177
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjZ3dS9xAEMAHqy--lNbPa1VWKeKDgXzvpn3y2h6HUMmDgm9hdrNBRXKHuSvcf9-ZTS56qNC3kJ2Q7M5OdjaZ-Q3AN1nGOsWEycdGe3FCNofk5npakTdgUJXalXv7c5WOb-LL2-R2DX4sc2FaPkT_wY0tw72v2cBRNy-MXE_vyMxVkH6ADU6tZXB-GOf9L4RYyrZ8AVMQA6U6rBCH8fSXri5GrzzM14GSLx1YtwKNPsHHznUUF62uP8OarbfgNG_Z04tzcf2cStWci1ORP1OpF9uQX6FDbAgOIudaSo3ARkwnMw4XotNYPsz_clCMmE2E4bnwJNrkrMV3kdN7sUuhFLarQ7oDN6Pf1z_HXldOwTPMePHiSKMxNPY20CajIxtVPmKVZTYIS9qslkZhEKWYGdq1Br6VaEJay8okpRNhGe3Cej2p7T4IGSRVWNHQGtQxYpKhSlVEt0mtTXVYDeBsOa6F6VjjXPLisVjuOUgFhVPBAE560WkL2HhL6GCpnKKzsaYII-lzPUEZDeC4bybr4F8eWNvJnGSoA5Ih-tkA9lpd9neJAobv-9QiV7TcCzB5e7Wlvr9zBG7pM4RHUTfdfHj_wYthPnYHX_5f9Ctshrypd4FuB7A-e5rbQ_J8ZvrIzfAj2LgY_hqO_gFfWwKP
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwED-N8QAvE98rDDAITTwsUuIktoN4AcRUYKvy0El7i86Oo4GmtFpbpP733Dlptmog8WbZFzn2-ew7--53AO90nVmFOSMfOxtlOckckpobWUPagENT25Du7XSixmfZ9_P8fAc-bmJhOnyI4cKNJSPs1yzgfCF9Q8rt_ILk3CTqDtzNlNQsljIrhzeETOsufwHDICbG9LhC7MczfLp9Gt1SMW97St7UYMMRdPwA9nrdUXzqmP0Qdnz7CA7LDnx6fSSm17FUiyNxKMprWOr1YygnGDA2BHuRczKlhcCFmM-W7C9E1Vj_Wv1mrxixnAnHi-FKdNFZ6w-ipI2xj6EUvk9E-gTOjr9Ov4yjPp9C5BjkJcpSi87R5PvEuoJKPm1ixKYofCJrslZrZzBJFRaOzNYk9hqdpMOszhVVyDp9CrvtrPX7IHSSN7KhqXVoM8S8QKNMSt0o75WVzQjeb-a1cj3YOOe8uKw2RgexoAosGMHbgXTeIWz8jehgw5yqF7JFJVMdc0JBnY7gzdBM4sFvHtj62YpoaACaUfSLETzreDn0kiaMvh9Ti97i8kDA0NvbLe3PiwDBrWNG4TE0zLAe_v3j1edyHArP_5_0NdwbT09PqpNvkx8v4L5kCz94vR3A7vJq5V-SGrS0r8Jq_wMr6gSJ
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjZ3dT9swEMBPjEloLwgGbOVjMxNCPBAp33a2p31VhW1VHkDiLTo7jrppSivaIvW_585JAxVM2ltkX5TY54vP8fl3ACeyjHWKCZOPjfbihGwOyc31tCJvwKAqtUv39muYDq7jy5vkZg0-Lc_CNHyI7ocbW4b7XrOBT8rqkZHryYjMXAXpC3jpNvsY6xzn3RZCLGWTvoApiIFSLVaIw3i6W1cnoyce5tNAyccOrJuB-luw2bqO4nOj621Ys_VrOM0b9vTiXFw9HKWanotTkT9QqRc7kA_RITYEB5FzLqWpwKmYjGccLkTFWP6Z33FQjJiNheGxcCuaw1mLjyKn72J7hFLYNg_pLlz3v199HXhtOgXPMOPFiyONxlDf20CbjK5sVPmIVZbZICxpsVoahUGUYmZo1Rr4VqIJaS4rk5QKwjLag_V6XNu3IGSQVGFFXWtQx4hJhipVET0mtTbVYdWDs2W_FqZljXPKi7_Fcs1BKiicCnrwoROdNICN54QOl8opWhubFmEkfc4nKKMeHHfVZB285YG1Hc9JhhogGaKf9eBNo8vuKVHA8H2fauSKljsBJm-v1tS_R47ALX2G8ChqphsP_37x4ks-cBf7_y_6Hjbyb_3i58XwxwG8Cnl972LeDmF9dju3R-QEzfQ7N9jvAagWA7s
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Natural+compounds+as+potential+adjuvants+to+cancer+therapy%3A+Preclinical+evidence&rft.jtitle=British+journal+of+pharmacology&rft.au=Lin%2C+Shian-Ren&rft.au=Chang%2C+Chia-Hsiang&rft.au=Hsu%2C+Che-Fang&rft.au=Tsai%2C+May-Jwan&rft.date=2020-03-01&rft.eissn=1476-5381&rft.volume=177&rft.issue=6&rft.spage=1409&rft_id=info:doi/10.1111%2Fbph.14816&rft_id=info%3Apmid%2F31368509&rft.externalDocID=31368509
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0007-1188&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0007-1188&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0007-1188&client=summon